Sebela Pharmaceuticals(R) Acquires Exclusive Licensing Rights ...
- Written by LATEST ASIANET NEWS RELEASES
- Published in Asia Net
BRAINTREE, Mass., Oct. 28, 2022 /PRNewswire-AsiaNet/ -- -- Phase 3 Trials Initiated with Tegoprazan for the Treatment ofErosive Esophagitis and Non-erosive Reflux DiseaseSebela Pharmaceuticals(R) has entered an exclusive partnership with HK inno.N Corporation to license tegoprazan in the ...
Authors: LATEST ASIANET NEWS RELEASES